newsfilter
← Latest News
Business Wire·

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

-- Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omeros' Zaltenibart Phase 3 Clinical Program in PNH -- Omeros Corporation (NASDAQ:OMER) today announced that two posters directed to